Press releases

Beactica wins grant to develop combination therapy for glioblastoma

Beactica AB, the Swedish drug discovery company, today announced that it has been awarded a grant of 2.8 MSEK (~$300 000) from SweLife and Medtech4Health for its project focused on finding effective therapies for glioblastoma, an aggressive form of brain cancer. Treatment methods for glioblastoma have shown no significant... [...]

Beactica to present at BioEquity Europe 2019

Beactica AB, the Swedish drug discovery company, today announced that it has been selected to present at the 20 th Annual BioEquity Europe 2019. The conference will take place on 20–21 May in Barcelona, Spain. Dr Per Källblad, Chief Executive Officer, to present on Monday 20 May 2019 at 2:20 PM. The location is the... [...]

Beactica, VIB and CD3 announce drug discovery alliance targeting inflammatory diseases

Beactica AB, the Swedish drug discovery company, today announced a new partnership with VIB and KU Leuven’s Centre for Drug Design and Discovery (CD3). The three parties will be working together in a drug discovery project to address critical unmet needs in the area of inflammation. The partnership goal is to generate... [...]

Beactica to present LSD1 programme at the AACR Annual Meeting 2019

Beactica AB, the Swedish drug discovery company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research’s Annual Meeting 2019. The conference will take place on 29 March – 3 April, 2019 at Georgia World Congress Center in Atlanta, USA. Dr Ulf... [...]

Beactica receives the Nordic Stars Award 2018

Beactica, the Swedish drug discovery company, today announced that it has been given the Nordic Stars Award 2018. The prize is handed out annually by SwedenBIO, the Swedish association for the life science industry, “ in special recognition of life science companies in the Nordic region demonstrating outstanding innovation... [...]

Beactica to present pipeline update at NLSDays

Beactica, the Swedish drug discovery company, today announced that it has been selected for a company presentation at NLSDays 2018 in Stockholm, on 11 th September. Per Källblad, CEO, will deliver an update on Beactica and its pipeline of novel cancer therapeutics during the first Pharmaceuticals Company Presentations... [...]